In a recent phase 2, randomised, double-blind trial, 281 patients with advanced cancer (NSCLC, PDAC, and CRC) were screened for cancer cachexia (defined by Fearon’s criteria [2]) and elevated serum GDF-15 levels (NCT05546476) [38]. This evidence concerns the gene GDF15 and cancer.